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Characterization of novel non-nucleoside reverse transcriptase (RT)
inhibitor resistance mutations at residues 132 and 135 in the 51 kDa
subunit of HIV-1 RT
Dwight V. NISSLEY*†, Jessica RADZIO‡, Zandrea AMBROSE§, Chih-Wei SHEEN‡, Noureddine HAMAMOUCH‡, Katie L. MOORE‖,
Gilda TACHEDJIAN‖¶ and Nicolas SLUIS-CREMER‡1
*Basic Research Program, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland 21702, U.S.A., †Gene Regulation and Chromosome Biology Laboratory, NCI-Frederick, Frederick,
Maryland 21702, U.S.A., ‡Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, U.S.A., §HIV Drug
Resistance Program, National Cancer Institute, Frederick, Maryland 21702, U.S.A., ‖Molecular Interactions Group, Macfarlane Burnet Institute for Medical Research and Public Health,
Melbourne, Victoria 3004, Australia, and ¶Department of Microbiology, Monash University, Clayton, Victoria 3168, Australia
Several rare and novel NNRTI [non-nucleoside reverse transcri-
ptase (RT) inhibitor] resistance mutations were recently detected
at codons 132 and 135 in RTs from clinical isolates using the
yeast-based chimaeric TyHRT (Ty1/HIV-1 RT) phenotypic assay.
Ile132 and Ile135 form part of the β7–β8 loop of HIV-1 RT (residues
132–140). To elucidate the contribution of these residues in RT
structure–function and drug resistance, we constructed twelve
recombinant enzymes harbouring mutations at codons 132 and
135–140. Several of the mutant enzymes exhibited reduced DNA
polymerase activities. Using the yeast two-hybrid assay for HIV-
1 RT dimerization we show that in some instances this decrease
in enzyme activity could be attributed to the mutations, in the
context of the 51 kDa subunit of HIV-1 RT, disrupting the subunit–
subunit interactions of the enzyme. Drug resistance analyses using
purified RT, the TyHRT assay and antiviral assays demonstrated
that the I132M mutation conferred high-level resistance
(>10-fold) to nevirapine and delavirdine and low-level resis-
tance (∼2–3-fold) to efavirenz. The I135A and I135M mutations
also conferred low level NNRTI resistance (∼2-fold). Subunit
selective mutagenesis studies again demonstrated that resistance
was conferred via the p51 subunit of HIV-1 RT. Taken together,
our results highlight a specific role of residues 132 and 135 in
NNRTI resistance and a general role for residues in the β7–β8
loop in the stability of HIV-1 RT.
Key words: chimaeric Ty1/HIV-1 reverse transcriptase phenotypic
assay, HIV-1, non-nucleoside reverse transcriptase inhibitor, resis-
tance, reverse transcriptase.
INTRODUCTION
HIV-1 RT (reverse transcriptase) is a multifunctional enzyme that
catalyses the conversion of the viral single-stranded RNA into
double-stranded DNA. Due to its essential role in HIV-1 replic-
ation, RT is a major target for the development of antiretroviral
agents [1]. To date, two therapeutic classes of RT inhibitors have
been identified: the NRTIs (nucleoside RT inhibitors) and the
NNRTIs (non-nucleoside RT inhibitors). NRTIs bind at the active
site of RT and act as competitive, chain-terminating inhibitors
of DNA polymerization [2]. By contrast, the NNRTIs bind to
a non-active site pocket in HIV-1 RT [termed the NNRTI-BP
(NNRTI-binding pocket)] and act as allosteric inhibitors of DNA
polymerization [3]. Although combinatorial therapies that contain
two or more RT inhibitors have profoundly reduced morbidity and
mortality associated with AIDS, their long-term efficacy is limited
by the selection of drug-resistant variants of HIV-1.
The detection and characterization of drug-resistant variants
is important for the effective management of HIV-1 infected
individuals. The TyHRT (Ty1/HIV-1 RT) assay, which uses hybrid
yeast Ty1/HIV-1 RT retroelements, was previously developed to
provide a simple phenotypic assay for HIV-1 RT activity [4].
Expression of TyHRT elements carrying a reverse transcription
indicator gene generates HIV-1 RT-mediated events at a high
frequency and the activity of HIV-1 RT variants can be differ-
entiated and characterized over a 10000-fold range. Since HIV-1
RT activity is inhibited by NNRTI in yeast [5], this assay can be
used to determine the inhibitor susceptibility of individual RTs
derived from laboratory clones or from clinical sample isolates
[6] and can be used to detect drug resistant viral variants present
at frequencies of less than 1% of the virus population [6,7]. In
this regard, we recently detected several rare and novel NNRTI
resistance mutations at codons 132 and 135, in particular I132M
and I135M, in HIV-1 RT [8,8a]. However, the genetic background
of the clinical RT isolates in these studies varied from canonical
WT (wild-type) strains and contained multiple polymorphisms
that may also have affected RT activity and inhibitor susceptibility.
Accordingly, the primary objective of the present study was to
elucidate the role of these residues in RT structure–function and
drug resistance in a defined RT background.
MATERIALS AND METHODS
Materials
TyHRT reverse transcription assays were carried out in Saccharo-
myces cerevisiae strain GRY 1990(MATα ura3–167 trp1:pgk-
lacZ spt3–101 his3200). Yeast two-hybrid analyses were carried
out using the S. cerevisiae strain CTY10–5d (MATα ade2
trp1–901 leu2-lacZ his3–200 gal4−gal80− URA3:lexA-lacZ).
Efavirenz and nevirapine were obtained from the NIH (National
Institutes of Health) AIDS Research and Reference Reagent
Abbreviations used: β-gal, β-galactosidase; p66, 66 kDa subunit of reverse transcriptase; p51, 51 kDa subunit of reverse transcriptase; RLU, relative
light unit; RT, reverse transcriptase; TyHRT, Ty1/HIV-1 RT; NNRTI, non-nucleoside RT inhibitor; NNRTI-BP, NNRTI-binding pocket; NRTI, nucleoside RT
inhibitor; WT, wild-type.
1 To whom correspondence should be addressed (email cremern@dom.pitt.edu).
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Program. Delavirdine was purchased from BIOMOL. All other
reagents were of the highest quality available and were used
without further purification.
Site-directed mutagenesis and purification of HIV-1 RT
All mutations were introduced into WT HIV-1LAI RT [9] by site-
directed mutagenesis using the QuikChange® mutagenesis kit
(Stratagene). Full-length sequencing of mutant RTs was per-
formed to confirm the presence of the desired mutations and to
exclude adventitious mutations introduced during mutagenesis.
WT and mutant recombinant HIV-1 RTs were overexpressed
and purified to homogeneity as described previously [10,11].
For subunit selective mutagenesis, the p66 (66 kDa subunit of
RT) and p51 (51 kDa subunit of RT) RT genes were cloned
into the pET-DUET vector (Novagen-EMD Biosciences) and
enzymes were purified as described previously using a double-tag
strategy [12,13]. The RT concentration was determined spectro-
photometrically at 280 nm using a molar absorption coefficient
(ε280) of 260450 M−1 cm−1.
RNA-dependent DNA polymerase assays
Fixed time assays were used for HIV-1 RT-associated RNA-
dependent DNA polymerase activity. Briefly, reactions were
carried out in 50 mM Tris/HCl (pH 7.8 at 37 ◦C), 50 mM KCl,
10 mM MgCl2 and 5 µg/ml of poly(rA)-oligo(dT)12−18 containing
20 µM [3H]TTP, and various concentrations of ligand dissolved in
DMSO (3% final concentration). Reactions were initiated by the
addition of 50 ng of WT RT, incubated for 20 min at 37 ◦C and then
quenched with 250 µl of ice-cold 10%TCA (trichloroacetic acid)
containing 20 mM sodium pyrophosphate. Quenched samples
were filtered and the extent of radionucleotide incorporation was
determined by liquid scintillation spectrometry.
CD spectroscopy
CD spectra were collected at ambient room temperature (24 ◦C)
using an Aviv Instruments Circular Dichroism Spectrometer
(Model 202). HIV-1 RT was dialysed into 500 mM sodium
phosphate buffer (pH 7.4) just prior to CD analysis.
Yeast two-hybrid assay
Quantification of protein–protein interactions were determined
using the β-gal (β-galactosidase) liquid assay performed on
permeablized yeast grown from at least three independent trans-
formants, as described previously [14]. Briefly, individual
transformants were grown in 1 ml of synthetic complete medium,
without histidine and leucine, containing 2% (w/v) glucose
(termed SC-His-Leu) at 30 ◦C with aeration for 16 h before
being diluted to an absorbance (at 600 nm) of 0.2 in 2.5 ml of
SC-His-Leu. Cells were then allowed to grow with aeration at
30 ◦C until the absorbance (at 600 nm) reached 0.5–0.8 before
they were pelleted and stored at −20 ◦C. Thereafter they were
permeablized in 50 µl of Y-PERTM Yeast Protein Extraction
Reagent (Pierce) and assayed for β-gal activity by adding 1 ml of
60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4
containing 40 mM 2-mercaptoethanol followed by the addition
of 200 µl of orthonitrophenyl-β-D-galactopyranoside. Reactions
were incubated at 30 ◦C, quenched by the addition of 0.5 ml of 1 M
Na2CO3, and the absorbance was read at 420 nm. β-gal activity
(in Miller units) was calculated by using the following equation:
Miller units = A420 × 1000/incubation time (in min).
Protein expression in yeast
To prepare yeast protein extracts for Western blot analysis, yeast
transformants were grown and pelleted as described above. To
extract protein, the cells were thawed at room temperature in
160 µl of YeastBuster Protein Extraction Reagent (Novagen)
containing 1 µg/ml of pepstatin, leupeptin and aprotinin. The cells
were vortexed for 10 s and allowed to mix on a rotating wheel
for 20 min at room temperature. The supernatant was clarified
after centrifugation at 13000 g for 15 min. The total protein
concentration for each protein extract was determined using
Bradford reagent (Bio-Rad) and 5–15 µg of total protein was
loaded per well for Western blot analysis. Fusion protein
expression in yeast was determined by Western blot analysis of
lysates with Gal4AD polyclonal antibodies (Upstate Biotechno-
logy) and anti-lexA polyclonal antibodies (Invitrogen). Immuno-
detection was accomplished using ECL®-Plus (Amersham).
TyHRT reverse transcription assay
TyHRT elements carrying a luciferase reverse transcription
reporter gene (TyHRT-lucAI) were used to assay RT activity
and inhibitor susceptibility in a yeast strain, GRY1990, where
lacZ is constitutively expressed and serves as a normalization
control. Assays were performed in a 96 well format by growing
cells carrying TyHRT-lucAI elements overnight in 0.5 ml of
AA-URA (amino-acid-supplemented synthetic medium lacking
uracil) + glucose in 2.2 ml deep-well plates. Then, 50 µl was
transferred to 0.5 ml AA-URA + galactose in 2.2 ml deep-well
plates and grown for 48 h without shaking at 30 ◦C. Subsequently,
50 µl was transferred to 200 µl of YPD [1% (w/v) yeast
extract/2% (w/v) peptone/2% (w/v) glucose] medium in 96 well
round-bottom tissue culture plates and grown for 6 h at 30 ◦C.
Cells were pelleted at 3000 g for 5 min, decanted and placed at
−80 ◦C for more than 30 min to promote cell lysis upon thawing.
Cells were resuspended in 160 µl of 1 mM Tris/HCl (pH 7.5)
and 0.1 mM EDTA at room temperature. The cell suspension
(80 µl) was then transferred to Microlite 1 (Thermo) flat-bottom
micotitre plates followed by the addition of 160 µl Enhanced
Luciferase Assay reagent (BD Pharmigen). Then 8 µl of cell
suspension was transferred to Microlite 1 (Thermo) flat-bottom
micotitre plates followed by the addition of 80 µl of Galacto-
Star (Applied Biosystem) reagent. Luciferase activity was read at
15 min and β-gal activity was read at 1 h in a 96 well luminometer
(Tropix TR717, Applied Biosytems). RT activity was determined
by dividing luciferase activity (RT reporter) RLUs (relative light
units) by β-gal (cell growth and lysis normalization) RLUs.
Drug-resistance assays were carried out in the presence of 0.4%
DMSO. Different RT inhibitor concentrations were achieved by
2-fold serial dilutions in AA-URA + galactose medium. In each
experiment RT mutations were run in triplicate and the RT assays
were repeated at least three times. RT activity assays in the
absence of drug were also carried out in a 96 well format with six
independent isolates of each variant and 24 WT RT controls per
plate.
In some instances, the standard deviations for activities
determined in the TyHRT-luciferase assay were high. This can be
attributed to the fact that this is an in vivo assay and, accordingly,
is subject to multiple variable parameters including the following.
(i) Assays are carried in an spt3 deletion strain to prevent
expression of endogenous Ty retroelements. Cells lacking the
SPT3 protein show pleiotropic phenotypes and the his3200
deletion impacts mitochondrial maintenance, galactose induction
and senescence. (ii) TyHRT elements are expressed from a
galactose-responsive promoter. Growth and promoter activity in
the presence of galactose varies due to genetic (including the
c© 2007 Biochemical Society
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Figure 1 Structural representation of nevirapine bound in the NNRTI-BP of
HIV-1 RT
The NNRTI-BP is formed predominantly from residues in the p66 subunit of HIV-1 RT. These
include Lys103, Val106, Tyr181 and Tyr188 (depicted). The β7–β8 loop in the p51 subunit of RT
(residues 132–140) is located at the base of the NNRTI-BP. Residues Ile132 and Ile135, however,
do not directly interact with the bound ligand. (In this structure, Ile132 and Ile135 are located
∼20 A˚ and 13 A˚ from nevirapine.) This Figure was generated using PDB co-ordinates 3HVT
and MOE software (Chemical Computing Group).
spt3 mutation) and environmental factors. (iii) Lysis of cells is
achieved via freeze/thaw of cell pellets and the extent of lysis
varies within a 96 well plate and from experiment to experiment.
(iv) Luciferase is measured in yeast cell extracts in the presence
of cellular proteases that degrade luciferase. These parameters
combine to contribute to the variability of the TyHRT-luciferase
assay.
Antiviral Assays
WT, I132M, and I135M HIV-1LAI virus stocks were made by
transfection of HEK-293T (human embryonic kidney 293T)
cells with the plasmids using LipofectamineTM 2000 (Invitrogen).
Viruses were titered on GHOST cells expressing CD4 and CXCR4
[15]. TZM indicator cells (formerly called JC53 BL13+ cells)
were infected in duplicate with each virus at an equal multiplicity
of infection in the presence or absence of 5-fold dilutions of
inhibitors, as previously described [16]. Each inhibition assay
was performed in two independent experiments.
RESULTS
Residues 132 and 135 form part of the β7–β8 loop (residues
132–140) in HIV-1 RT. In the 66 kDa (p66) subunit of RT, this
loop is situated in the fingers domain and resides a substantial
distance from both the DNA polymerase active site and NNRTI-
BP. In the 51 kDa (p51) subunit of RT, the β7–β8 loop is situated
in the dimer interface and contributes to the formation of the
base of the NNRTI-BP (Figure 1). However, Ile132 and Ile135 do
not directly interact with the bound ligand nor do they form part
of the NNRTI-BP (Figure 1). Accordingly, we hypothesized that
mutations at residues 132 and 135 in HIV-1 RT might decrease
the susceptibility of the enzyme to NNRTI by inducing subtle
conformational changes in the β7–β8 loop that influence the
ability of other residues to interact optimally with the bound
ligand. Therefore in the present study we have characterized
mutations at residues 132 (I132A and I132M) and 135 (I135A
and I135M) to elucidate their specific roles in NNRTI resistance.
We also performed alanine scanning mutagenesis of residues
136–140 to delineate the roles of each of these residues in
NNRTI resistance. Furthermore, RT containing E138K or T139V
was included in the present study since these mutations have
previously been associated with NNRTI resistance [17,18].
Figure 2 Activity ofmutant HIV-1 RT determined using recombinant purified
enzymes or the TyHRT assay
Data are reported as an average +− S.D. of at least three separate experiments. The grey and
black bars represent the fold-change in RT activity using recombinant purified enzymes (grey
bars) or the TyHRT assay (black bars). *P < 0.01 compared with WT (Student’s t test).
Activity of WT and mutant HIV-1 RT
As described above, we generated 11 mutant HIV-1 RT constructs
that harboured the following mutations: I132A, I132M, I135A,
I135M, N136A, N137A, E138A, E138K, T139A, T139V or
P140A. Each of the mutant enzymes was purified to homogeneity
and analysed for RNA-dependent DNA polymerase activity. The
mutant RT constructs were also introduced into the TyHRT system
and their relative reverse transcription activities were assessed
using a luciferase-based reverse transcription reporter. In general,
the activities of each of the mutant enzymes were similar in
both assay systems (Figure 2), although some differences can
be noted. These differences may be due to the fact that TyHRT
activity is dependent on multiple RT functions whereas only RNA-
dependent DNA polymerase activity was assessed for the purified
recombinant enzymes. Of note, the substitutions I132A, I132M,
I135M and E138K were well tolerated by HIV-1 RT. By contrast,
the activities of the I135A, N136A, N137A, E138A, T139A,
T139V and P140A enzymes were compromised.
Far-UV CD analyses of WT and mutant HIV-1 RT
To determine whether the reduced activity of the mutant enzymes
was a result of protein misfolding, far-UV CD spectroscopic
analyses of WT and mutant HIV-1 RT were performed. The CD
spectra for WT and all mutant enzymes, except for the N136A
RT, were essentially identical (Figure 3) indicating that these
mutations did not impact on the spatial arrangement or secondary
structure of the peptide backbone. In regard to N136A HIV-1
RT, a recent study also demonstrated that mutations at this codon
perturb the secondary structure of the enzyme [19]. Therefore
the loss of reverse transcription activity associated with the
N136A mutation may be due to protein-associated conformational
changes.
Role of β7–β8 loop in RT heterodimer stability
The DNA polymerase activity of HIV-1 RT is tightly coupled
to the quaternary structure of the enzyme [20,21]. Because the
β7–β8 loop resides in the dimer interface where many of the resi-
dues participate in the subunit–subunit interactions of RT
[19,22–24], we were interested to determine whether the loss
of DNA polymerase activity associated with the I135A, N136A,
N137A, E138A, T139A, T139V and P140A mutations was related
to defects in subunit dimerization. Accordingly, we analysed the
ability of these mutant enzymes to form functional heterodimers
c© 2007 Biochemical Society
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Figure 3 Far-UV CD spectra of WT and mutant HIV-1 RT
Figure 4 Effect of mutations on the β-gal readout in the yeast two-hybrid
RT dimerization assay
Yeast reporter strain CTY10-5d was co-transformed with p66 bait and p51 prey constructs
containing mutations in β7–β8 and assayed for β-gal activity. β-gal activity (abscissa)
represents the average of three transformants from three independent experiments. *P < 0.01
compared with WT (Student’s t test).
using the yeast two-hybrid assay [14] (Figure 4). In this assay
system, p66 was fused to the LexA DNA-binding domain ‘the
bait’ and p51 was fused to the Gal4 activation domain (GalAD)
‘the prey’. Specific interaction between the two subunits resulted
in trans-activation of the Lac Z reporter gene in the yeast strain
CTY10–5d, which permits the interaction for the RT subunits
to be quantified by assaying for β-gal activity. Initially, β-gal
activity in yeast co-expressing mutant p66 bait and p51 prey
fusions engineered with the same mutations in each subunit
was measured. This analysis revealed that the substitutions
I135A, N136A and E138A significantly decreased β-gal activity
compared with yeast expressing the WT p66 bait and p51 fusion
proteins (Figure 4). To delineate the effects of mutations in each
of the subunits on RT dimerization, we performed a subunit-
selective analysis. To analyse the effects of mutations in the
p66 subunit we co-transformed yeast with mutant p66 bait and
WT p51 prey, and to analyse the effects of mutations in the p51
subunit we co-transformed yeast with WT p66 bait and mutant
p51 prey. Our data show that the mutations in the p51 subunit were
largely responsible for the observed decrease in β-gal activity
(Figure 4).
Decreases in β-gal activity, as measured in a yeast two-hybrid
assay, may represent a true diminution in RT subunit interaction or
may be due to decreased expression levels of either the bait or prey
fusions compared with WT protein. To distinguish between these
two possibilities we compared the steady-state protein levels in
yeast expressing mutant p66 bait and p51 prey fusion proteins
with the WT proteins. Yeast protein extracts were prepared
from exponentially growing cells and subjected to Western blot
analysis. The p66 bait was detected using LexA antibodies and
p51 prey detected using Gal4AD antibodies. No differences
in the steady-state protein levels of the p66 bait or p51 prey
c© 2007 Biochemical Society
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Table 1 NNRTI susceptibility of WT and mutant HIV-1 RT
The concentrations of NNRTI required to inhibit the activity of purified RT and TyHRT by 50 % (IC50) are reported as an average of three independent experiments +− S.D. The effective concentrations
of NNRTI required to inhibit virus replication by 50 % (EC50) are reported as an average of two independent experiments +− S.D. Values in parentheses indicate fold-resistance.
IC50/EC50
RT Assay Efavirenz (nM) Nevirapine (µM) Delavirdine (µM)
WT Purified RT 94.16 +− 6.33 (1.0) 7.22 +− 1.38 (1.0) 2.18 +− 0.62 (1.0)
TyHRT 1.73 +− 0.64 (1.0) 1.16 +− 0.55 (1.0) *
Antiviral 0.90 +− 0.00 (1.0) 0.03 +− 0.00 (1.0) 0.04 +− 0.01 (1.0)
I132A Purified RT 90.07 +− 5.11 (1.0) 18.05 +− 2.35 (2.5) 8.70 +− 1.02 (4.0)
TyHRT 2.78 +− 0.97 (1.6) 1.95 +− 0.52 (1.7) *
I132M Purified RT 432.42 +− 11.31 (4.6) 62.09 +− 3.69 (8.6) 30.25 +− 3.35 (13.9)
TyHRT 6.63 +− 2.43 (3.7) 7.10 +− 1.67 (6.1) *
Antiviral 2.00 +− 0.00 (2.2) 1.25 +− 1.10 (42) 0.80 +− 0.20 (20.0)
I135A Purified RT 188.08 +− 9.34 (2.0) 87.36 +− 4.56 (12.1) 34.60 +− 5.59 (15.9)
TyHRT 1.62 +− 0.47 (0.9) 1.63 +− 0.58 (1.4) *
I135M Purified RT 197.09 +− 13.18 (2.1) 38.99 +− 2.89 (5.4) 3.92 +− 0.99 (1.8)
TyHRT 2.76 +− 1.15 (1.6) 2.02 +− 0.50 (1.7) *
Antiviral 2.00 +− 0.00 (2.2) 0.07 +− 0.01 (2.3) 0.05 +− 0.02 (1.3)
N136A†
N137A Purified RT 87.35 +− 22.28 (0.9) 6.50 +− 1.10 (0.9) 1.52 +− 0.55 (0.7)
TyHRT 1.30 +− 0.14 (0.8) 1.28 +− 0.37 (1.1) *
E138A Purified RT 188.08 +− 12.11 (2.0) 13.72 +− 1.57 (1.9) 7.62 +− 0.91 (3.5)
TyHRT 4.11 +− 2.09 (2.4) 1.19 +− 1.03 (1.0) *
E138K Purified RT 216.34 +− 12.13 (2.3) 15.88 +− 2.26 (2.2) 13.06 +− 1.56 (6.0)
TyHRT 3.52 +− 1.04 (2.0) 1.51 +− 0.75 (1.3) *
T139A†
T139V Purified RT 113.44 +− 9.23 (1.2) 12.27 +− 1.89 (1.7) 2.61 +− 0.97 (1.2)
TyHRT 1.74 +− 0.85 (1.0) 1.85 +− 0.24 (1.6) *
P140A†
*Delavirdine is not soluble in yeast media.
†RT activity too low to effectively evaluate NNRTI susceptibility.
Table 2 NNRTI susceptibility of HIV-1 RT containing subunit specific
mutations
The concentrations of NNRTI required to inhibit the activity of purified RT by 50 % (IC50) are
reported as an average of three independent experiments +− S.D. Values in parentheses indicate
fold-resistance.
IC50
Efavirenz (nM) Nevirapine (µM) Delavirdine (µM)
p66WT/p51WT 15.44 +− 3.16 (1.0) 5.21 +− 1.08 (1.0) 1.68 +− 0.50 (1.0)
p66I132M/p51I132M 69.08 +− 9.02 (4.6) 44.80 +− 4.26 (8.6) 23.35 +− 2.56 (13.9)
p66I132M/p51WT 15.34 +− 4.46 (1.0) 5.20 +− 1.05 (1.0) 1.60 +− 0.85 (1.0)
p66WT/p51I132M 78.19 +− 10.05 (5.2) 47.93 +− 6.36 (9.2) 21.33 +− 3.85 (12.7)
p66I135M/p51I135M 32.11 +− 1.09 (2.1) 28.13 +− 3.36 (5.4) 3.02 +− 0.45 (1.8)
p66I135M/p51WT 15.37 +− 8.02 (1.0) 4.91 +− 1.25 (0.9) 1.70 +− 0.55 (1.0)
p66WT/p51I132M 35.36 +− 1.19 (2.3) 25.52 +− 2.88 (4.9) 3.86 +− 0.35 (2.3)
p66E138K/p51E138K 35.17 +− 1.29 (2.3) 11.46 +− 2.77 (2.2) 10.08 +− 2.22 (6.0)
p66E138K/p51WT 15.21 +− 7.03 (1.0) 5.00 +− 1.10 (1.0) 1.64 +− 0.65 (1.0)
p66WT/p51E138K 36.22 +− 9.02 (2.4) 12.50 +− 3.20 (2.4) 10.25 +− 2.70 (6.1)
mutants were observed compared with the WT subunits (results
not shown). This result indicates that the observed decreases in
β-gal activity were entirely due to a diminution in RT subunit
interactions.
NNRTI susceptibility of WT and mutant HIV-1 RT
The NNRTI susceptibility of WT and mutant HIV-1 RT to
efavirenz, nevirapine and delavirdine was assessed in three com-
plementary assay systems. These included analyses of recom-
binant purified RT, the TyHRT assay and antiviral assays in TZM
indicator cells (Table 1). In each of the assays, the I132M mutation
conferred high-level resistance (> than 10-fold) to nevirapine and
delavirdine and low-level resistance (∼2-fold) to efavirenz. The
I132A mutation conferred low-level resistance to nevirapine and
delavirdine in assays that used purified RT. The I135M mutation
also conferred low-level resistance (∼2-fold) to all NNRTIs tested
in each of the assays, whereas the I135A mutation conferred high-
level resistance to nevirapine and delavirdine, but not to efavirenz,
only at the enzyme level. By contrast, all other mutations, with
the exception of the E138A and E138K mutations, conferred
essentially no resistance to each of the NNRTIs tested.
To delineate the effects of I132M, I135M and E138K in each
of the RT subunits on NNRTI susceptibility, we performed a
subunit-selective analysis using purified enzyme that harboured
each mutation in either the p66 or p51 subunit. The data (Table 2)
clearly demonstrate that the NNRTI resistance is conferred by the
mutations present in the p51, and not p66, subunit.
NRTI susceptibility of WT and mutant HIV-1 RT
The susceptibility of recombinant purified WT and mutant HIV-
1 RT to the NRTI AZT-TP (3′-azido-3′-dideoxythymidine tri-
phosphate), ddTTP (3′-dideoxythymidine triphosphate) and d4T-
TP (2′,3′-didehydrothymidine triphosphate) was also assessed.
These data (Table 3) demonstrated that none of the mutant
enzymes exhibited any changes in susceptibility to each of the
nucleoside analogue inhibitors tested.
DISCUSSION
The detection and characterization of minor drug-resistant
variants is important for the clinical management of HIV infection
c© 2007 Biochemical Society
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Table 3 NRTI susceptibility of WT and mutant HIV-1 RT.
The concentrations of NRTI required to inhibit the activity of purified RT by 50 % (IC50) are
reported as an average of three independent experiments +− S.D. Values in parentheses indicate
fold-resistance
IC50 (µM)
ddTTP AZT-TP d4T-TP
WT 0.10 +− 0.05 (1.0) 0.06 +− 0.01 (1.0) 0.20 +− 0.02 (1.0)
I132A 0.07 +− 0.02 (0.7) 0.02 +− 0.01 (0.3) 0.13 +− 0.03 (0.7)
I132M 0.06 +− 0.01 (0.6) 0.03 +− 0.01 (0.5) 0.12 +− 0.04 (0.6)
I135A 0.08 +− 0.02 (0.8) 0.04 +− 0.01 (0.6) 0.16 +− 0.05 (0.8)
I135M 0.09 +− 0.03 (0.9) 0.06 +− 0.01 (1.0) 0.17 +− 0.05 (0.9)
N136A *
N137A 0.10 +− 0.04 (1.0) 0.06 +− 0.02 (1.0) 0.18 +− 0.04 (0.9)
E138A 0.09 +− 0.02 (0.9) 0.03 +− 0.01 (0.5) 0.16 +− 0.06 (0.8)
E138K 0.10 +− 0.03 (1.0) 0.07 +− 0.02 (1.2) 0.16 +− 0.06 (0.8)
T139A *
T139V 0.10 +− 0.05 (1.0) 0.06 +− 0.02 (1.0) 0.14 +− 0.06 (0.7)
P140A *
* RT activity too low to effectively evaluate NRTI susceptibility.
and for studies dissecting the mechanisms of antiretroviral
treatment failure. Using the TyHRT phenotypic assay, we detected
unusual and rare NNRTI resistance mutations at codons 132
and 135 in RTs (in particular I132M and I135M) from clinical
isolates [6–8]. Other studies have also detected NNRTI resistance-
associated mutations at codon 135 in HIV-1 RT [18,25]. In the
present study we demonstrate that these mutations confer NNRTI
resistance both at the virus and enzyme level. In fact, the I132M
mutation conferred high-level resistance (>10-fold) to nevirapine
and delavirdine in each of the assay systems tested.
HIV-1 RT is a heterodimer composed of a 66 kDa (p66) subunit
and a p66-derived 51 kDa (p51) subunit [26]. Our subunit selective
mutagenesis studies demonstrated that I132M and I135M confer
NNRTI resistance via the p51, and not p66, subunit of HIV-1
RT. In p51, the β7–β8 subunit (residues 132–140) resides in the
dimer interface and contributes to the base of the NNRTI-BP
(Figure 1). However, Ile132 and Ile135 do not interact with the
bound ligand nor do they directly form part of the NNRTI-BP. As
described in the Results section, we hypothesized that mutations
at Ile132 and Ile135 may decrease NNRTI susceptibility by acting
through other residues in the β7–β8 loop. Accordingly, we also
carried out alanine-scanning mutagenesis studies of residues 136–
140. Interestingly, most of these mutations significantly decreased
the activity of RT. CD and yeast two-hybrid analyses suggested
that for some enzymes this was due to either a conformational
change induced in RT structure (N136A) or a defect in RT
heterodimer formation (I135A, N137A and E138A). These results
are consistent with previously published studies which have
demonstrated a key role for the β7–β8 loop in RT stability [19,22–
24]. For the T139A, T139V and P140A mutations, however,
the loss of RT activity could not be attributed to either a
conformational change in RT structure or heterodimer instability.
It should be noted though that previous studies suggested an
important role for Thr139 and Pro140 in RT dimerization [23,24].
Despite the discrepancies between the present study and those
carried out by Auwerx et al. [23,24], taken together our combined
results highlight an important role for these residues in RT
structure and function.
Whereas mutations at residues 132 and 135 in RT conferred
NNRTI resistance, mutations at residues 137, 139 and 140 had
no effect on drug susceptibility. The results are consistent with
previous in-depth mutagenesis studies which demonstrated that
residues 137, 139 and 140 did not influence NNRTI susceptibility
[23,24]. NNRTI resistance mutations, however, have been
selected at residue Thr139 but these are mostly associated with
resistance to (+)-calanolide A and do not affect the sensitivity of
nevirapine, delavirdine and efavirenz [23]. By contrast, mutations
at residue 138 can significantly affect NNRTI susceptibility
(the present study and [27–29]). Thus it might be possible that
mutations at residues 132 and 135 affect NNRTI susceptibility
via Glu138. A crystal structure of E138K HIV-1 RT in complex
with nevirapine has recently been solved [30]. These data show
that Glu138 indirectly interacts with the bound ligand via water
molecules, and that the E138K mutation alters these interactions
resulting in a small shift in the position of nevirapine, which may
influence its ring stacking with Tyr181 [30]. We hypothesize that the
I132M and I135M mutations may affect β7–β8 loop positioning
and the concomitant interactions of Glu138 with the bound ligand.
However, crystal structure analyses of I132M and I135M RTs in
complex with NNRTI are required to confirm this hypothesis.
This research was supported in part by the NIH (National Institutes of Health) grant
R01 GM068406-01 (to N. S.-C.) and with federal funds from the NCI (National Cancer
Institute), NIH, under contract N01-CO-12400 (to D. V. N.). G. T. was supported by NHMRC
(National Health and Medical Research Council) RD Wright Career Development Award
235102 and K. L. M. by NHMRC Project Grant 381703. The content of this publication
does not necessarily reflect the views or policies of the Department of Health and Human
Services, nor does mention of trade names, commercial products, or organizations imply
endorsement by the U.S. Government.
REFERENCES
1 Tsai, C. H., Lee, P. Y., Stollar, V. and Li, M. L. (2006) Antiviral therapy targeting viral
polymerase. Curr. Pharm. Des. 12, 1339–1355
2 Goody, R. S., Muller, B. and Restle, T. (1991) Factors contributing to the inhibition of HIV
reverse transcriptase by chain-terminating nucleotides in vitro and in vivo. FEBS Lett.
291, 1–5
3 De Clercq, E. (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs)
in the therapy of HIV-1 infection. Antiviral Res. 38, 153–179
4 Nissley, D. V., Garfinkel, D. J. and Strathern, J. N. (1996) HIV reverse transcription in
yeast. Nature 380, 30
5 Nissley, D. V., Boyer, P. L., Garfinkel, D. J., Hughes, S. H. and Strathern, J. N. (1998)
Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1
reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 95, 13905–13910
6 Nissley, D. V., Halvas, E. K., Hoppman, N. L., Garfinkel, D. J., Mellors, J. W. and Strathern,
J. N. (2005) Sensitive phenotypic detection of minor drug-resistant human
immunodeficiency virus type 1 reverse transcriptase variants. J. Clin. Microbiol. 43,
5696–5704
7 Halvas, E. K., Aldrovandi, G. M., Balfe, P., Beck, I. A., Boltz, V. F., Coffin, J. M., Frenkel,
L. M., Hazelwood, J. D., Johnson, V. A., Kearney, M. et al. (2006) Blinded, multicenter
comparison of methods to detect a drug-resistant mutant of human immunodeficiency
virus type 1 at low frequency. J. Clin. Microbiol. 44, 2612–2614
8 Flys, T., Nissley, D. V., Claasen, C. W., Jones, D., Shi, C., Guay, L. A., Musoke, P.,
Mmiro, F., Strathern, J. N., Jackson, J. B. et al. (2005) Sensitive drug-resistance assays
reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP)
resistance mutation in some women and infants after the administration of single-dose
NVP: HIVNET 012. J. Infect. Dis. 192, 24–29
8a Nissley, D. V., Julias, J., Mellors, J. W., Hughes, S. H. and Strathern, J. N. (2004)
Detection and characterization of rare drug resistant HIV-1 RT variants using a sensitive
phenotypic assay. Antiviral Ther. 9, S140
9 Shi, C. and Mellors, J. W. (1997) A recombinant retroviral system for rapid in vivo
analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase
inhibitors. Antimicrob. Agents Chemother. 41, 2781–2785
10 Le Grice, S. F., Cameron, C. E. and Benkovic, S. J. (1995) Purification and
characterization of human immunodeficiency virus type 1 reverse transcriptase.
Methods Enzymol. 262, 130–144
11 Le Grice, S. F. and Gruninger-Leitch, F. (1990) Rapid purification of homodimer and
heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography.
Eur. J. Biochem. 187, 307–314
c© 2007 Biochemical Society
Novel NNRTI resistance mutations in HIV-1 RT 157
12 Maier, G., Dietrich, U., Panhans, B., Schroder, B., Rubsamen-Waigmann, H., Cellai, L.,
Hermann, T. and Heumann, H. (1999) Mixed reconstitution of mutated subunits of HIV-1
reverse transcriptase coexpressed in Escherichia coli-two tags tie it up. Eur. J. Biochem.
261, 10–18
13 Miranda, L. R., Gotte, M., Liang, F. and Kuritzkes, D. R. (2005) The L74V mutation in
human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced
excision of zidovudine monophosphate associated with thymidine analog resistance
mutations. Antimicrob. Agents Chemother. 49, 2648–2656
14 Tachedjian, G., Aronson, H. E. and Goff, S. P. (2000) Analysis of mutations and
suppressors affecting interactions between the subunits of the HIV type 1 reverse
transcriptase. Proc. Natl. Acad. Sci. U.S.A. 97, 6334–6339
15 Zhang, Y. J., Dragic, T., Cao, Y., Kostrikis, L., Kwon, D. S., Littman, D. R., KewalRamani,
V. N. and Moore, J. P. (1998) Use of coreceptors other than CCR5 by non-syncytium-
inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare
in vitro. J. Virol. 72, 9337–9344
16 Ambrose, Z., Boltz, V., Palmer, S., Coffin, J. M., Hughes, S. H. and Kewalramani, V. N.
(2004) In vitro characterization of a simian immunodeficiency-human immunodeficiency
virus (HIV) chimera expressing HIV Type 1 reverse transcriptase to study antiviral
resistance in pigtail macaques. J. Virol. 78, 13553–13561
17 Balzarini, J., Karlsson, A., Sardana, V. V., Emini, E. A., Camarasa, M. J. and De Clercq, E.
(1994) Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT)
inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1
mutants or select for highly resistant (Y181C → C181I)RT HIV-1 mutants. Proc. Natl.
Acad. Sci. U.S.A. 91, 6599–6603
18 Gao, Y., Paxinos, E., Galovich, J., Troyer, R., Baird, H., Abreha, M., Kityo, C.,
Mugyenyi, P., Petropoulos, C. and Arts, E. J. (2004) Characterization of a subtype D
human immunodeficiency virus type 1 isolate that was obtained from an untreated
individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.
J. Virol. 78, 5390–5401
19 Balzarini, J., Auwerx, J., Rodriguez-Barrios, F., Chedad, A., Farkas, V.,
Ceccherini-Silberstein, F., Garcia-Aparicio, C., Velazquez, S., De Clercq, E., Perno, C. F.
et al. (2005) The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains
efficient association of both RT subunits and enables the rational design of novel RT
inhibitors. Mol. Pharmacol. 68, 49–60
20 Restle, T., Muller, B. and Goody, R. S. (1990) Dimerization of human immunodeficiency
virus type 1 reverse transcriptase. A target for chemotherapeutic intervention.
J. Biol. Chem. 265, 8986–8988
21 Tachedjian, G., Radzio, J. and Sluis-Cremer, N. (2005) Relationship between enzyme
activity and dimeric structure of recombinant HIV-1 reverse transcriptase. Proteins 60,
5–13
22 Pandey, P. K., Kaushik, N., Talele, T. T., Yadav, P. N. and Pandey, V. N. (2001) The β7-β8
loop of the p51 subunit in the heterodimeric (p66/p51) human immunodeficiency virus
type 1 reverse transcriptase is essential for the catalytic function of the p66 subunit.
Biochemistry 40, 9505–9512
23 Auwerx, J., Rodriguez-Barrios, F., Ceccherini-Silberstein, F., San-Felix, A., Velazquez, S.,
De Clercq, E., Camarasa, M. J., Perno, C. F., Gago, F. and Balzarini, J. (2005) The role of
Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to
(+)-calanolide A. Mol. Pharmacol. 68, 652–659
24 Auwerx, J., Van Nieuwenhove, J., Rodriguez-Barrios, F., de Castro, S., Velazquez, S.,
Ceccherini-Silberstein, F., De Clercq, E., Camarasa, M. J., Perno, C. F., Gago, F. and
Balzarini, J. (2005) The N137 and P140 amino acids in the p51 and the P95 amino acid in
the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are
instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
FEBS Lett. 579, 2294–2300
25 Leigh-Brown, A. J., Precious, H. M., Whitcomb, J. M., Wong, J. K., Quigg, M., Huang, W.,
Daar, E. S., D’Aquila, R. T., Keiser, P. H., Connick, E. et al. (2000) Reduced susceptibility of
human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to
nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino
acid sites. J. Virol. 74, 10269–10273
26 Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A. and Steitz, T. A. (1992) Crystal
structure at 3.5 A˚ resolution of HIV-1 reverse transcriptase complexed with an inhibitor.
Science 256, 1783–1790
27 Sato, A., Hammond, J., Alexander, T. N., Graham, J. P., Binford, S., Sugita, K.,
Sugimoto, H., Fujiwara, T. and Patick, A. K. (2006) In vitro selection of mutations in human
immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine,
a novel nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 70, 66–74
28 Hazen, R. J., Harvey, R. J., St Clair, M. H., Ferris, R. G., Freeman, G. A., Tidwell, J. H.,
Schaller, L. T., Cowan, J. R., Short, S. A., Romines, K. R. et al. (2005) Anti-human
immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor
GW678248 in combination with other antiretrovirals against clinical isolate viruses and
in vitro selection for resistance. Antimicrob. Agents Chemother. 49, 4465–4473
29 Ferris, R. G., Hazen, R. J., Roberts, G. B., St Clair, M. H., Chan, J. H., Romines, K. R.,
Freeman, G. A., Tidwell, J. H., Schaller, L. T., Cowan, J. R. et al. (2005) Antiviral activity
of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor.
Antimicrob. Agents Chemother. 49, 4046–4051
30 Ren, J., Nichols, C. E., Stamp, A., Chamberlain, P. P., Ferris, R., Weaver, K. L., Short, S. A.
and Stammers, D. K. (2006) Structural insights into mechanisms of non-nucleoside drug
resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138. FEBS J. 273,
3850–3860
Received 5 December 2006/24 January 2007; accepted 8 February 2007
Published as BJ Immediate Publication 8 February 2007, doi:10.1042/BJ20061814
c© 2007 Biochemical Society
